Plain-English translation of NCT07161271 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial examines a specialized medical device called ECCO2R (extracorporeal carbon dioxide removal) that helps remove excess carbon dioxide directly from the bloodstream in patients with severe breathing failure in the ICU. Researchers want to understand whether a gentler, low-flow version of this device works well and is safe for patients, since previous studies showed the older, higher-flow versions caused more complications. This study reviews real patient records from 2022 to 2024 to see how well the treatment performed.
While earlier trials of this treatment improved how patients' lungs worked, they didn't clearly help patients survive longer, and the older versions caused serious complications. Doctors in Hong Kong believe that using a gentler, low-flow version of the device might work better with fewer side effects, and this study aims to confirm that observation.
You likely qualify if…
You likely don't qualify if…
This is a retrospective study, which means researchers will review your medical records from your time in the ICU — you won't need to visit the hospital or undergo any new procedures. The study team will collect information about your care, how the device worked, and your health outcomes to better understand the safety and effectiveness of this treatment.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Hong Kong
Enrollment target
~59 participants
Started
November 2024
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wai Ching Simon Sin, Director, Clinical Professor
Hong Kong University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.